Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 4;45(2):171-189.
doi: 10.1210/endrev/bnad027.

Obesity-Related Hypogonadism in Women

Affiliations
Review

Obesity-Related Hypogonadism in Women

Pei Chia Eng et al. Endocr Rev. .

Abstract

Obesity-related hypogonadotropic hypogonadism is a well-characterized condition in men (termed male obesity-related secondary hypogonadism; MOSH); however, an equivalent condition has not been as clearly described in women. The prevalence of polycystic ovary syndrome (PCOS) is known to increase with obesity, but PCOS is more typically characterized by increased gonadotropin-releasing hormone (GnRH) (and by proxy luteinizing hormone; LH) pulsatility, rather than by the reduced gonadotropin levels observed in MOSH. Notably, LH levels and LH pulse amplitude are reduced with obesity, both in women with and without PCOS, suggesting that an obesity-related secondary hypogonadism may also exist in women akin to MOSH in men. Herein, we examine the evidence for the existence of a putative non-PCOS "female obesity-related secondary hypogonadism" (FOSH). We précis possible underlying mechanisms for the occurrence of hypogonadism in this context and consider how such mechanisms differ from MOSH in men, and from PCOS in women without obesity. In this review, we consider relevant etiological factors that are altered in obesity and that could impact on GnRH pulsatility to ascertain whether they could contribute to obesity-related secondary hypogonadism including: anti-Müllerian hormone, androgen, insulin, fatty acid, adiponectin, and leptin. More precise phenotyping of hypogonadism in women with obesity could provide further validation for non-PCOS FOSH and preface the ability to define/investigate such a condition.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Mechanisms of hypogonadism in male obesity-related secondary hypogonadism (MOSH). Abbreviations: GnRH, gonadotropin releasing hormone; LH, luteinizing hormone; FSH, follicle stimulating hormone; SHBG, sex hormone binding globulin; NEFA, Non-esterified fatty acids; IL, interleukin; TNF-α, tumor necrosis factor.
Figure 2.
Figure 2.
Mechanisms of polycystic ovary syndrome (PCOS) in lean women. Abbreviations: GnRH, gonadotropin releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone–binding globulin; E2, estradiol; AMH, anti-Müllerian hormone; PCOS, polycystic ovary syndrome.
Figure 3.
Figure 3.
Putative mechanisms of female obesity-related secondary hypogonadism in women with obesity. Abbreviations: GnRH, gonadotrophin releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; SHBG, sex hormone–binding globulin; E2, estradiol; AMH, anti-Müllerian hormone; PCOS, polycystic ovarian syndrome; NEFA, nonesterified fatty acids; IL, interleukin; TNF-α, tumor necrosis factor.

References

    1. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017;14(4):435. - PMC - PubMed
    1. World Health Organization . Obesity and Overweight. WHO; 2021.
    1. Ampofo AG, Boateng EB. Beyond 2020: modelling obesity and diabetes prevalence. Diabetes Res Clin Pract. 2020;167:108362. - PubMed
    1. Rich-Edwards J, Spiegelman D, Garland M, et al. . Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002;13(2):184‐190. - PubMed
    1. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism—pathophysiology, clinical implications and management. Eur Endocrinol. 2019;15(2):83‐90. - PMC - PubMed